Company intelligence / Profile preview

DPBIO

Unknown, California, United States

Ownership: Private
Development stage: Other

Overview

DPBIO is a global leader in droplet microfluidics, providing high-throughput single-cell analysis platforms that accelerate antibody discovery, enzyme evolution, and cancer research. Its Cytospark™ system can screen millions of single cells rapidly to identify functional antibodies against complex targets. Recent partnerships demonstrate the platform’s ability to significantly reduce drug discovery timelines from months to days[3].

Modalities: Monoclonal antibodySingle-domain antibodyEnzyme
Industry: Drug Discovery Services

Partnerships

Leveragen (strategic partnership for advanced antibody drug development)

Beyond the preview

Go deeper on DPBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPBIO.

Explore the full profile